AstraZeneca strikes obesity deal with China's CSPC Pharmaceuticals
(Alliance News) - AstraZeneca PLC on Friday said it has expands its weight-management pipeline by collaborating with China's CSPC Pharmaceuticals Group Ltd to develop next-generation injectable therapies for obesity and type 2 diabetes. Read More